IRWD Ironwood Pharmaceuticals, Inc.
Company Analysis
Latest News
🔴 Ironwood Pharmaceuticals is trading 5% down today with biotech weakness a possible factor
Ironwood Pharmaceuticals is trading 5.31% down at $3.57 as of 9:56 a.m. ET on October 16, 2026; broader biotech weakness may be contributing, though no...
🔴 Ironwood Pharmaceuticals is trading 5% down in pre-market — no confirmed catalyst identified
Ironwood Pharmaceuticals is trading at $3.56, down 5.48%, in pre-market; no specific confirmed catalyst has been identified. - On October 16, Ironwood...
Ironwood Pharmaceuticals Appoints Tammi Gaskins as New CEO, Effective Jan 1, 2027
Ironwood Pharmaceuticals announced that its Board of Directors has appointed Tammi Gaskins, the company's current Senior Vice President and Chief Commercial...
🟢 Ironwood Pharmaceuticals is trading 5% up amid broader biotech gains
Ironwood Pharmaceuticals is trading 5.03% higher at $3.78 as of 10:39 a.m. ET on October 15, 2026; broader biotech strength may be supporting the move. - No...
🔴 Ironwood Pharmaceuticals is trading 5% down today after FDA seeks confirmatory Phase 3 trial
Ironwood Pharmaceuticals is trading at $3.56, down 5.32%, after the FDA sought a new confirmatory Phase 3 trial before considering apraglutide approval for...
🟢 Ironwood Pharmaceuticals is trading 5.33% up
Ironwood Pharmaceuticals is trading higher, with no clear company-specific or market catalyst identified. - Trading at $3.95, up 5.33%. - No October 8 company...
🔴 Ironwood Pharmaceuticals is trading 6.7% down in after-hours trading; no new catalyst identified
Ironwood Pharmaceuticals is trading at $3.50 (-6.67%) in after-hours trading, with the cause of the decline unclear. - Its investor-relations page lists no...
🟢 Ironwood Pharmaceuticals is trading 5% up
Ironwood Pharmaceuticals is trading at $3.81, up 5.10%, with no confirmed company-specific announcement or report explaining the October 7 session gain. -...
🔴 Ironwood Pharmaceuticals is trading 5% down; no fresh company-specific catalyst identified
Ironwood Pharmaceuticals is trading 5.04% lower at $3.77, with no fresh company-specific catalyst identified. - The investor-relations press-release page lists...
🔴 Ironwood Pharmaceuticals is trading 5% down today as broader risk-off trading pressured equities
Ironwood Pharmaceuticals is trading 5.08% lower at $4.29, in a decline that appears mainly aligned with broader risk-off trading; no clear company-specific...
🟢 Ironwood Pharmaceuticals is trading 5% up today as broader markets rally
Ironwood Pharmaceuticals is trading 5.05% up now at $4.58 as broader markets rally; no September 21, 2026 company-specific catalyst has been identified. • The...
🟢 Ironwood Pharmaceuticals is trading 5% up today amid biotech gains after Federal Reserve decision
Ironwood Pharmaceuticals is trading 5.19% up at $4.39, primarily amid a broader biotech-sector rally and improved risk appetite following the Federal Reserve...
🟢 Ironwood Pharmaceuticals is trading 5% up today as biotech stocks rise with broader market
Ironwood Pharmaceuticals is trading 5.21% up now at $4.34, primarily alongside biotech-sector gains in a broadly stronger market; no clear company-specific...
🔴 Ironwood Pharmaceuticals is trading 6% down in pre-market; no clear catalyst identified
Ironwood Pharmaceuticals is trading 5.81% down at $3.89, with no clear company-specific catalyst identified for August 25, 2026. - Ironwood raised 2026...
🔴 Ironwood Pharmaceuticals is trading 5% down today amid broad biotech-sector retreat
Ironwood Pharmaceuticals is trading at $4.13 (-5.30%) as biotechnology stocks retreat broadly. - The sector is down 2.47%, while the Nasdaq Composite is down...
🟢 Ironwood Pharmaceuticals is trading 5.4% up today — no clear catalyst identified
Ironwood Pharmaceuticals is trading 5.4% higher at $4.30, with no clear catalyst identified for the move. - This reverses the August 13, 2026 close of...
🔴 Ironwood Pharmaceuticals is trading 5.4% down today with no clear company-specific catalyst
Ironwood Pharmaceuticals is trading 5.4% down at $4.08, with no clear company-specific catalyst identified in August 13, 2026 coverage. - Recent...
🟢 Ironwood Pharmaceuticals is trading 5% up today after 2026 guidance increase
Ironwood Pharmaceuticals is trading 5% up now at $4.25 as investors continue reacting to the August 6 earnings update and raised 2026 guidance. - LINZESS U.S....
🔴 Ironwood Pharmaceuticals is trading 5% down today after second-quarter revenue missed estimates
Ironwood Pharmaceuticals is trading 5% down now at $4.10 after second-quarter revenue missed estimates. - Investors continued weighing mixed second-quarter...
Ironwood Pharmaceuticals' second quarter EPS beats as strong LINZESS sales drive a FY2026 guidance raise.
Ironwood Pharmaceuticals reported second quarter 2026 total revenue of $113.0 million and GAAP diluted EPS of $0.31. While revenue missed consensus estimates...